166 related articles for article (PubMed ID: 10601613)
21. Hypotonic intrapleural cisplatin chemotherapy as treatment for pleural carcinomatosis in an experimental model.
Katano K; Tsujitani S; Saito H; Ikeguchi M; Maeta M; Kaibara N
Anticancer Res; 1997; 17(6D):4547-52. PubMed ID: 9494566
[TBL] [Abstract][Full Text] [Related]
22. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.
Opitz I; Lardinois D; Arni S; Hillinger S; Vogt P; Odermatt B; Rousson V; Weder W
Eur J Cardiothorac Surg; 2007 May; 31(5):773-8. PubMed ID: 17350855
[TBL] [Abstract][Full Text] [Related]
23. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G
Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
25. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861.
Figlin R; Mendoza E; Piantadosi S; Rusch V
Chest; 1994 Dec; 106(6 Suppl):363S-366S. PubMed ID: 7988265
[TBL] [Abstract][Full Text] [Related]
26. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
[TBL] [Abstract][Full Text] [Related]
27. An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma.
Ellithy MM; El Baghdady NS; El Wakeel LM; Abdeltawab KA; Badary OA
Am J Clin Oncol; 2013 Oct; 36(5):514-8. PubMed ID: 22781392
[TBL] [Abstract][Full Text] [Related]
28. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.
van Ruth S; van Tellingen O; Korse CM; Verwaal VJ; Zoetmulder FA
Anticancer Drugs; 2003 Jan; 14(1):57-65. PubMed ID: 12544259
[TBL] [Abstract][Full Text] [Related]
30. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
31. Intrapleural etoposide for malignant effusion.
Holoye PY; Jeffries DG; Dhingra HM; Holmes FA; Raber M; Engineer MS; Newman RA
Cancer Chemother Pharmacol; 1990; 26(2):147-50. PubMed ID: 2189591
[TBL] [Abstract][Full Text] [Related]
32. Intrapleural cisplatin for management of malignant pleural effusion in a patient with plasma cell leucaemia.
Agarwal A; Klair J; Patolia S; Meena NK
BMJ Case Rep; 2015 Jun; 2015():. PubMed ID: 26123465
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer.
Katano K; Tsujitani S; Maeta M; Fukuda K; Oka S; Hisamitsu K; Ikeguchi M; Kaibara N
Oncol Rep; 2001; 8(3):605-9. PubMed ID: 11295088
[TBL] [Abstract][Full Text] [Related]
34. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.
Lombardi G; Nicoletto MO; Gusella M; Fiduccia P; Dalla Palma M; Zuin A; Fiore D; Donach M; Zagonel V
Cancer Chemother Pharmacol; 2012 Mar; 69(3):781-7. PubMed ID: 22037881
[TBL] [Abstract][Full Text] [Related]
35. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894
[TBL] [Abstract][Full Text] [Related]
36. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion.
Astoul P; Viallat JR; Laurent JC; Brandely M; Boutin C
Chest; 1993 Jan; 103(1):209-13. PubMed ID: 8417880
[TBL] [Abstract][Full Text] [Related]
37. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
Nakano T; Chahinian AP; Shinjo M; Togawa N; Tonomura A; Miyake M; Ninomiya K; Yamamoto T; Higashino K
Cancer; 1999 Jun; 85(11):2375-84. PubMed ID: 10357408
[TBL] [Abstract][Full Text] [Related]
39. [Current value of intrapleural fibrinolysis in the treatment of exudative fibrinous pleural effusions in pleural empyema and hemothorax].
Kemper P; Köhler D
Pneumologie; 1999 Aug; 53(8):373-84. PubMed ID: 10483276
[TBL] [Abstract][Full Text] [Related]
40. Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?
Porta C; Rizzo V; Zimatore M; Sartore-Bianchi A; Danova M; Mutti L
Lung Cancer; 2002 Nov; 38(2):159-62. PubMed ID: 12399127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
